公开(公告)号：US20160152579A1

公开(公告)日：2016-06-02

申请号：US14904228

申请日：2014-07-11

申请人： CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) ,  SERVICIO ANDALUZ DE SALUD ,  FUNDACIÓN PÚBLICA ANDALUZA PARA LA INVESTIGACIÓN DE MÁLAGA EN BIOMEDICINA Y SALUD (FIMABIS)

发明人： Ruth Pérez Fernández ,  María Nieves Fresno López ,  José Elguero Bertolini ,  Pilar Goya Laza ,  Ana Belén Torres Zaguirre ,  Fernando Rodíguez De Fonseca ,  Francisco Javier Pavón Morón ,  Manuel Macías González ,  Miguel Romero Cuevas

IPC分类号： C07D263/22 ,  A61K8/49 ,  A61K31/421

CPC分类号： C07D263/22 ,  A61K8/49 ,  A61K31/421 ,  A61K2800/10 ,  A61Q19/00

摘要： The present invention relates to a family of differently substituted oxazolidinones and to the pharmaceutically acceptable salts, esters, prodrugs, tautomers, solvates and hydrates thereof, which show affinity for the alpha and gamma subtypes of the peroxisome proliferator-activated receptors (PPAR) and which, therefore, modulate the actions regulated by said receptors, such as inducing satiety, controlling ingestion and modulating metabolic effects, and thus are useful for the administration thereof as a pharmacological tool and as drugs for the treatment and/or prevention of metabolic diseases and cardiovascular diseases.

摘要翻译： 本发明涉及一种不同取代的恶唑烷酮族及其药学上可接受的盐，酯，前药，互变异构体，溶剂合物和水合物，其显示出对过氧化物酶体增殖物激活受体（PPAR）的α和γ亚型的亲和性， 因此，调节由所述受体调节的作用，例如诱导饱腹感，控制摄取和调节代谢作用，因此可用于作为药物作用和作为用于治疗和/或预防代谢性疾病和心血管的药物 疾病